StockNews.AISignal intelligence
INmune Bio, Inc. · NASDAQ · Healthcare
Browse public INMB signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Martin Shkreli predicts a 90% drop for INMB shares. Shkreli cites weak Phase 1 trial data as a major concern. Recent enthusiasm followed INMB's 44% surge relating to XPro1595. BMF Reports supports Shkreli's critique of INMB's scientific integrity. INMB shares fell by 15% on Friday ahead of Shkreli's post.
View signal analysisINMB's stock is down 59%, trading at $2.14. Volume spiked to 23.2 million, significantly above average. Phase 2 trial results showed cognitive benefits for XPro in OBAD patients. INMB plans to file for Breakthrough Therapy Designation with the FDA. Company aims to define pivotal trial path in Q4 2025.
View signal analysisINmune Bio's Alzheimer’s drug fails mid-stage trial, shares drop 59%. Failure to improve cognitive functions significantly impacts investor confidence.
View signal analysisINMB stock surged 74.68% with high trading volume. Company to present Phase 2 MINDFuL trial data on June 30. XPro shows promising potential in treating Alzheimer's disease. Trial overenrolled with 208 patients categorized as mild AD and MCI. Strong correlation found between EMACC and CDR-SB in Alzheimer's assessment.
View signal analysis